Fibrosis CRO Selection Criteria 2026: 7 Evaluation Axes
Fibrosis CRO selection: 7 axes (disease coverage, models, quantification, regulatory, cost, IP, logistics) plus BIOSECURE Act and FDA MA 3.0 implications.
Why you need seven independent evaluation axes
Choosing a fibrosis CRO is not a simple matter of consulting a neutral five-CRO landscape comparison. The same CRO can be excellent for MASH deep dives but weak in IPF, world-class in 3D in vitro yet outsourcing GLP animal work, or low-cost yet ALCOA+ deficient and therefore an FDA inspection risk. The optimal choice shifts dramatically with project objectives.
This guide breaks down the seven independent evaluation axes most often missed in fibrosis CRO selection, framed as a practical checklist. Every item can be assessed from public information at the RFP and proposal stages, so buyers (project leaders, BD, procurement) can narrow candidates without relying on subjective marketing language. Pair this article with the five trends driving specialty CRO selection, the neutral five-CRO landscape, and the MASH in vitro 3D platform comparison.
Quick reference: the 7-axis scorecard
| # | Axis | Public signal | RFP question |
|---|---|---|---|
| 1 | Disease coverage | Website × literature DB | Coverage matrix across 6 organs (liver/lung/kidney/heart/skin/GI) |
| 2 | Model depth and validation | PubMed, LITMUS | Validation publications, LITMUS scores |
| 3 | Fibrosis quantification | Press releases | Sirius Red / HYP / AI pathology / Spatial Tx |
| 4 | Regulatory experience | FDA inspections, GLP | GLP / IND-enabling counts |
| 5 | Cost structure | Industry benchmarks | Unit price + rerun-risk total cost |
| 6 | IP and data export | Contract draft | Data residency, molecule rights, governing law |
| 7 | Logistics | Site geography | Shipping lanes, dual-sourcing, timelines |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
1. Disease coverage: a 6-organ map
Why this matters
Fibrosis spans liver, lung, kidney, heart, skin, and GI. Surface-level "fibrosis capability" claims often mask MASH-only experience. Real coverage depth determines project fit.
What to verify
- For how many of the six organs does the CRO maintain validated models?
- How many publications and conference abstracts in each organ in the past three years?
- Has the CRO run studies using approved or late-stage compounds (resmetirom, efruxifermin) as positive controls?
How to verify
Cross-reference the "Capabilities" or "Disease Models" section of the website against PubMed (CRO name + indication) over five years. CROs participating in the LITMUS consortium hold an advantage in MASH. See the pulmonary fibrosis model selection guide and renal fibrosis model comparison for organ-specific yardsticks.
2. Model depth and validation
Why this matters
"Has a model" and "has a translatable model" are different. With preclinical non-reproducibility at 51-89%, only multiply-validated models support Phase 3 readiness.
What to verify
- Public model documentation (induction, duration, histologic progression, serum dynamics)
- Third-party citations (Google Scholar, Web of Science)
- LITMUS consortium standardized scoring (MASH)
- ARRIVE 2.0-compliant SOPs and PREPARE guideline adoption
How to verify
Search PubMed by "CRO name + model name" over five years; the most-cited models are the most defensible. Examples include the LITMUS-ranked Gubra GAN-DIO MASH model, bleomycin mouse models (offered by multiple CROs), and UUO/IRI (renal model comparison).
3. Fibrosis quantification: a stack that does not lose signal
Why this matters
Fibrosis evaluation reliability comes from combining Sirius Red, hydroxyproline, AI pathology, and spatial transcriptomics. Single-method dependence misses drug response.
What to verify
- Sirius Red quantification: automated image analysis (QuPath, Visiopharm, Aiforia)
- Hydroxyproline assay: HPLC reference vs colorimetric
- AI pathology: HALO AI, PathAI, Aiforia deployments
- Spatial transcriptomics: Visium, CosMx
- Serum biomarkers: FIB-4, ELF, PRO-C3, ECM turnover overview, comprehensive MASLD/MASH biomarkers, non-invasive biomarker review
How to verify
The "Endpoints" or "Histology Services" pages on the CRO website, plus press releases and KOL talks, expose the actual platforms in use.
4. Regulatory experience: GLP and IND-enabling
Why this matters
FDA Modernization Act 3.0 (Senate-passed December 2025) institutionalizes NAMs qualification, but GLP animal studies remain the IND-enabling backbone. CROs that can architect hybrid animal + NAMs designs hold scarcity value during the transition.
What to verify
- Five-year GLP study count by indication
- FDA inspection history (483 form issuance)
- IND-enabling package delivery record
- NAMs (organ-on-chip, organoid, in silico) co-design capability
- Phase 3-relevant preclinical experience including resmetirom-class comparators
How to verify
The FDA Inspection Classification Database surfaces 483 history. Public patents and prior IND filings often cite the contributing CRO, providing indirect signals.
Related: For the full IND-enabling nonclinical safety package required before FIH, see ICH M3(R2) Roadmap: Nonclinical Package Before FIH Trials — five mandatory domains, Table 1 duration matrix, EU/US/JP regional differences.
5. Cost structure: total cost over unit price
Why this matters
Cheapest-CRO selection ignores rerun risk and schedule slippage. With reproducibility under pressure, the real cost metric is "delivers Phase 3-ready data on the first run."
What to verify
- Quoted unit price (per animal, per endpoint)
- Protocol amendment frequency over the past three years (a leading indicator of overrun cost)
- Principal Investigator turnover
- Rerun rates (rarely public, but referenceable from past customer interviews)
- In-house vs subcontracted work ratios (high subcontracting compresses margins on quality control)
How to verify
Anchor pricing against industry reports (Grand View Research, Pharmaceutical Outsourcing) and obtain three competing quotes to flag outliers.
6. IP and data export: navigating BIOSECURE
Why this matters
The BIOSECURE Act (FY2026 NDAA, signed December 18, 2025) restricts U.S. federal funding flowing to China-related CROs and CDMOs. Enforcement ramps over up to 970 days (~2 years 8 months), with a 5-year transition for existing contracts. Programs targeting U.S. approval are consolidating into FDA-inspectable jurisdictions.
What to verify
- Governing law for data and molecule information (US/EU vs China vs Japan)
- Data export clauses (return of analytical data after study completion)
- IP assignment terms (any improvement clauses)
- Molecule retention periods (CRO retention obligation vs deletion)
- 1260H list relationships of parent or subsidiary entities
How to verify
Scrutinize the contract draft and verify parent-company location and shareholding. Foley Hoag, Morrison Foerster, and similar law firm publications track the latest compliance posture.
7. Logistics: dual sourcing and timelines
Why this matters
42% of global pharma companies experienced geopolitical supply-chain disruption in 2025 (PharmiWeb 2026). Single-CRO, single-region dependence is risk concentration. Nearshoring grew 28-35% and "China+1" became the default sourcing strategy.
What to verify
- Site geography (US, EU, Japan, China)
- Animal and reagent supply chains (tariff exposure)
- Sample shipping timelines (GLP retention, cold chain)
- Dual-sourcing capability (parallel execution of identical protocols across two regions)
- Disaster recovery process (pandemic, geopolitical disruption)
How to verify
The "Locations" page combined with past disruption events (press releases, trade press) yields a defensible logistics view.
8. Implementation: building a 7-axis scorecard for the RFP
Assign each axis a weight (project-dependent) and a score (1-5), then take the weighted average to rank candidates.
| Axis | Project A weight (MASH F4 IND-enabling) | Project B weight (IPF discovery POC) |
|---|---|---|
| 1 Disease coverage | 0.25 | 0.30 |
| 2 Model depth | 0.20 | 0.20 |
| 3 Quantification | 0.15 | 0.15 |
| 4 Regulatory | 0.20 | 0.05 |
| 5 Cost | 0.05 | 0.15 |
| 6 IP / BIOSECURE | 0.10 | 0.05 |
| 7 Logistics | 0.05 | 0.10 |
Project A weights regulatory experience for IND readiness; Project B emphasizes cost for early discovery. Hide weights from CRO bidders, send identical questions to all candidates, and score internally — this is the recommended procurement practice.
Bottom line: independent axes defeat marketing language
The single biggest selection mistake is trusting modifiers like "cutting-edge," "specialized," or "highly reproducible" at face value. Evaluating each of the seven axes independently against public evidence — websites, publications, regulatory data, contract terms — moves the decision from gut feel to defensible analysis.
For specific CRO candidates see the neutral five-CRO landscape comparison; for trend context see the five trends driving specialty CRO selection; for MASH-specific in vitro 3D platforms see the MASH CRO comparison; for IPF specifically see the IPF preclinical CRO comparison.
Related articles
- Fibrosis CRO Landscape 2026: 5-CRO Neutral Comparison
- Five Trends Driving Specialty CRO Selection 2026
- MASH In Vitro 3D Liver Model CRO Comparison
- IPF Preclinical CRO Comparison
- Pulmonary Fibrosis Model Selection Guide
- Renal Fibrosis Model Comparison
- Fibrosis Quantification Three-Method Comparison
- Sirius Red Staining Complete Guide
- Hydroxyproline Assay Guide
- AI Pathology and Fibrosis Evaluation
- Spatial Transcriptomics in Fibrosis
- FIB-4 Score Complete Guide
- PRO-C3 Clinical Use Guide
- Resmetirom Post-Approval MASH Strategy
- Efruxifermin (HARMONY/SYMMETRY)